Earnings Summary

Anika Therapeutics Inc’s revenue jumped 3.35% since last year same period to $37.92Mn in the Q1 2023. On a quarterly growth basis, Anika Therapeutics Inc has generated -4.29% fall in its revenue since last 3-months.

Anika Therapeutics Inc’s net profit fell -252.88% since last year same period to $-10.35Mn in the Q1 2023. On a quarterly growth basis, Anika Therapeutics Inc has generated -110.88% fall in its net profits since last 3-months.

Anika Therapeutics Inc’s net profit margin fell -241.43% since last year same period to -27.29% in the Q1 2023. On a quarterly growth basis, Anika Therapeutics Inc has generated -120.32% fall in its net profit margins since last 3-months.

Anika Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a 4% jump from last quarter’s estimates.

Anika Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.24.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Anika Therapeutics Inc’s return on assets (ROA) stands at -0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Anika Therapeutics Inc’s return on equity (ROE) stands at -0.08.